Eris Lifesciences Limited has informed the Exchange about Investor Presentation
ERIS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Eris Lifesciences reported Q1 FY26 consolidated revenue of Rs. 773 cr, up 7.4% YoY, with EBITDA growing 11% to Rs. 277 cr (margin up 106 bps to 35.8%) and PAT jumping 41% to Rs. 125 cr. The Domestic Branded Formulations (DBF) business grew 11%, outpacing the Indian pharma market by ~330 bps, with DBF operating margins expanding 155 bps to 37%. The Biocon segment margin improved sharply to 30% (from 19% at acquisition), and finance costs fell ~20% YoY on faster debt repayment. Key strategic updates include commissioning of insulin vial manufacturing at Bhopal, Bhopal cartridge line expected in Q4 FY26, Semaglutide (GLP-1) launch on track for March 2026, and CDMO business with confirmed contracts worth Rs. 100+ cr p.a. kicking off from FY27. FY26 guidance reaffirmed: revenue Rs. 3,325-3,500 cr, EBITDA Rs. 1,190-1,255 cr, EPS growth of 50%, and net debt-to-EBITDA target of 1.5x by year-end.
Strong margin expansion and 41% PAT growth signal a healthy earnings trajectory, while the debt reduction roadmap and FY27 CDMO revenue visibility should support investor confidence. The Semaglutide pipeline adds a long-term growth lever, though the ramp-down of Trade Gx (Rs. 5+ cr EBITDA loss) and insulin supply shortages (Rs. 10 cr revenue loss in Q1) remain near-term drags.